{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:16:49Z","timestamp":1781111809228,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1186\/s12916-021-02012-6","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T01:05:26Z","timestamp":1622768726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Renin-angiotensin system blockers and COVID-19"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-7302","authenticated-orcid":false,"given":"Emmanuelle","family":"Vidal-Petiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"2012_CR1","doi-asserted-by":"publisher","first-page":"624052","DOI":"10.3389\/fphys.2021.624052","volume":"12","author":"SB Gressens","year":"2021","unstructured":"Gressens SB, Leftheriotis G, Dussaule J-C, Flamant M, Levy BI, Vidal-Petiot E. Controversial roles of the renin angiotensin system and its modulators during the COVID-19 pandemic. Front Physiol. 2021;12:624052. https:\/\/doi.org\/10.3389\/fphys.2021.624052.","journal-title":"Front Physiol."},{"key":"2012_CR2","doi-asserted-by":"publisher","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3). https:\/\/doi.org\/10.1093\/jtm\/taaa041.","DOI":"10.1093\/jtm\/taaa041"},{"key":"2012_CR3","doi-asserted-by":"publisher","first-page":"603736","DOI":"10.3389\/fphar.2021.603736","volume":"12","author":"RP Rothlin","year":"2021","unstructured":"Rothlin RP, Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli HM, et al. Angiotensin receptor blockers for COVID-19: pathophysiological and pharmacological considerations about ongoing and future prospective clinical trials. Front Pharmacol. 2021;12:603736. https:\/\/doi.org\/10.3389\/fphar.2021.603736.","journal-title":"Front Pharmacol."},{"issue":"3","key":"2012_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7326\/M20-1515","volume":"173","author":"K Mackey","year":"2020","unstructured":"Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020;173(3):195\u2013203. https:\/\/doi.org\/10.7326\/M20-1515.","journal-title":"Ann Intern Med."},{"issue":"2","key":"2012_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/HJH.0000000000002658","volume":"39","author":"A Lahens","year":"2021","unstructured":"Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, et al. Association between renin\u2013angiotensin\u2013aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. J Hypertens. 2021;39(2):367\u201375. https:\/\/doi.org\/10.1097\/HJH.0000000000002658.","journal-title":"J Hypertens."},{"issue":"4","key":"2012_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/HJH.0000000000002706","volume":"39","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, D\u2019Agostino McGowan L, Jensen ET, Rigdon J, South AM. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker use during COVID-19: beyond confounding. J Hypertens. 2021;39(4):795\u2013805. https:\/\/doi.org\/10.1097\/HJH.0000000000002706.","journal-title":"J Hypertens."},{"issue":"3","key":"2012_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","volume":"9","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275\u201384. https:\/\/doi.org\/10.1016\/S2213-2600(20)30558-0.","journal-title":"Lancet Respir Med."},{"issue":"3","key":"2012_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254\u201364. https:\/\/doi.org\/10.1001\/jama.2020.25864.","journal-title":"JAMA."},{"issue":"Supplement_1","key":"2012_CR9","doi-asserted-by":"publisher","first-page":"i48","DOI":"10.1093\/ckj\/sfab026","volume":"14","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, South AM, Shaltout HA, Sinclair MR, Sparks MA. Renin\u2013angiotensin system blockade in the COVID-19 pandemic. Clin Kidney J. 2021;14(Supplement_1):i48\u201359.","journal-title":"Clin Kidney J"},{"key":"2012_CR10","doi-asserted-by":"publisher","unstructured":"de Abajo FJ, Rodr\u00edguez-Miguel A, Rodr\u00edguez-Mart\u00edn S, Lerma V, Garc\u00eda-Lled\u00f3 A, et al. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. BMC Med 19, 118 (2021). https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/s12916-021-01992-9, 1","DOI":"10.1186\/s12916-021-01992-9"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02012-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T01:05:28Z","timestamp":1622768728000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02012-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2012"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02012-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}